Adaptive BiotechnologiesADPT +3.51%67 Days Payable is 39.22 as of Mar. 2026, which is 3% above its 10-year median of 37.94. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.06 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Adaptive Biotechnologies ranks worse than 72.77% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's Days Payable distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Adaptive Biotechnologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (ADPT) has a Days Payable of 39.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adaptive Biotechnologies and its competitors. This is near median its historical median of 37.94. Over the past decade, Adaptive Biotechnologies' Days Payable has ranged from 24.22 to 62.29. According to the industry distribution chart, Adaptive Biotechnologies ranks #139 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 72.8%.
Is Adaptive Biotechnologies' Days Payable too high?
Adaptive Biotechnologies' current Days Payable of 39.22 is near median its 10-year median of 37.94. Over the past 10 years, this metric has ranged from a low of 24.22 to a high of 62.29. The Medical Diagnostics & Research industry median Days Payable is 68.87. Adaptive Biotechnologies' value of 39.22 is 43.1% below this industry median. Based on the distribution chart, Adaptive Biotechnologies ranks #139 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Days Payable compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #139 out of 191 companies for Days Payable. This places Adaptive Biotechnologies in the lower half of its industry. The industry median Days Payable is 68.87. Adaptive Biotechnologies' value of 39.22 is 43.1% below this benchmark. Historically, Adaptive Biotechnologies' own Days Payable has ranged from 24.22 to 62.29 over the past decade. While the company's 10-year median is 37.94 vs. the industry median of 68.87, Adaptive Biotechnologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adaptive Biotechnologies's current Days Payable of 39.22 is 43.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current Days Payable is 39.22, which is near median its own 10-year median of 37.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.06, compared to a current price of $20.96 — trading 108.3% above its estimated fair value. The current Days Payable is 39.22, which is near median its 10-year median of 37.94 and 43.1% below the Medical Diagnostics & Research industry median of 68.87. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Days Payable is 39.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of $20.96 is trading 108.3% above its estimated GF Value™ of $10.06.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for ADPT:
Days Payable: 39.22 (near median its 10-year median of 37.94)
GF Value™: $10.06 vs. price of $20.96 (108.3% above fair value)
Industry Position: 43.1% below the Medical Diagnostics & Research median (#139 of 191)
No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
67GF Score
Get the complete analysis for ADPT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADPT has been successfully added to your 
